ストックスクリーナーアプリを入手
26.03
2.58%
-0.69
アフターアワーズ：
26.03
前日終値:
$26.72
開ける：
$26.86
24時間の取引高:
272.06K
Relative Volume:
0.44
時価総額：
$2.02B
収益：
$384.10M
当期純損益:
$-9.07M
株価収益率:
-185.93
EPS:
-0.14
ネットキャッシュフロー:
$11.10M
1週間 パフォーマンス:
-5.86%
1か月 パフォーマンス:
+30.80%
6か月 パフォーマンス:
+13.87%
1年 パフォーマンス:
+28.93%
1日の値動き範囲:
$26.01
$27.14
1週間の範囲:
$25.97
$28.56
52週間の値動き範囲:
$17.38
$28.56
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile
名前
Kiniksa Pharmaceuticals International Plc
セクター
電話
(781) 431-9100
住所
23 OLD BOND STREET, FLOOR 3, LONDON
KNSA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KNSA
Kiniksa Pharmaceuticals International Plc
|
26.03 | 2.02B | 384.10M | -9.07M | 11.10M | -0.14 |
|
ZTS
Zoetis Inc
|
159.27 | 70.23B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.74 | 48.23B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.36 | 48.22B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.93 | 18.57B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
301.42 | 13.29B | 2.76B | 1.11B | 898.10M | 22.77 |
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-13 | 開始されました | Citigroup | Buy |
| 2024-09-13 | 開始されました | Jefferies | Buy |
| 2024-05-03 | 開始されました | Wells Fargo | Overweight |
| 2020-06-29 | 繰り返されました | BofA Securities | Buy |
| 2020-04-01 | 開始されました | BofA/Merrill | Buy |
| 2019-03-11 | 開始されました | Barclays | Overweight |
| 2018-12-12 | 繰り返されました | Wedbush | Outperform |
| 2018-06-19 | 開始されました | JMP Securities | Mkt Outperform |
すべてを表示
Kiniksa Pharmaceuticals International Plc (KNSA) 最新ニュース
Kiniksa Pharmaceuticals CEO sells shares worth $218,866 By Investing.com - Investing.com Nigeria
Kiniksa Pharmaceuticals CEO sells shares worth $218,866 - Investing.com Australia
Kiniksa Pharmaceuticals: Making Steady Progress (NASDAQ:KNSA) - Seeking Alpha
Insider’s View: Deciphering Kiniksa Pharmaceuticals International Plc (KNSA)’s Financial Health Through Ratios - DWinneX
How should investors view Kiniksa Pharmaceuticals International Plc (KNSA)? - uspostnews.com
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $2,265,339, According to a Recent SEC Filing - marketscreener.com
Kiniksa Pharmaceuticals Executives Sell Shares - TradingView
Wall Street analysts’ outlook for Kiniksa Pharmaceuticals International Plc (KNSA) - Sete News
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q1 2025 Earnings Call Transcript - Insider Monkey
3 Stocks Including Kiniksa Pharmaceuticals International That May Be Priced Below Intrinsic Value Estimates - simplywall.st
Kiniksa Pharmaceuticals International PLC (KNSA) Q1 2025: Everyt - GuruFocus
Examining the Potential Price Growth of Kiniksa Pharmaceuticals International Plc (KNSA) - knoxdaily.com
Kiniksa (KNSA) Partners with Carly Pearce for Health Awareness C - GuruFocus
Kiniksa (KNSA) Partners with Carly Pearce for Health Awareness Campaign | KNSA Stock News - GuruFocus
Kiniksa Pharmaceuticals International Plc (KNSA) Stock: A Year of Decreases and Increases - investchronicle.com
Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis - GlobeNewswire
Country Star Carly Pearce Opens Up About 4-Year Struggle With Rare Heart Disease in New Campaign - Stock Titan
An Intrinsic Calculation For Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Suggests It's 41% Undervalued - Yahoo Finance
Kiniksa raises ARCALYST 2025 revenue guidance to $605M amid strong Q1 performance - MSN
Decoding Kiniksa Pharmaceuticals International PLC (KNSA): A Str - GuruFocus
Wedbush Raises Price Target on Kiniksa Pharmaceuticals to $36 From $34, Maintains Outperform Rating - marketscreener.com
Kiniksa Pharmaceuticals: A Biotech Stock on the Rise, But What’s Next? - RagingBull
Kiniksa Pharmaceuticals International, plc Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Kiniksa Pharmaceuticals Surpasses Q1 2025 Revenue Estimates with $137.8 Million, EPS Details Unavailable - GuruFocus
Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Res - GuruFocus
KNSA Reports Strong Q1 Revenue and Updates ARCALYST Sales Foreca - GuruFocus
Kiniksa Pharmaceuticals Swings to Q1 Net Income, Revenue Increases - marketscreener.com
KNSA: Kiniksa Forecasts Increased ARCALYST Revenue for 2025 | KN - GuruFocus
Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution - The Manila Times
Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results - TradingView
Earnings Flash (KNSA) Kiniksa Pharmaceuticals International Posts Q1 EPS $0.11, vs. FactSet Est of $0.13 per Share - marketscreener.com
Kiniksa Q1 Earnings: ARCALYST Revenue Soars 75% to $138M, 2025 Guidance Boosted to $605M - Stock Titan
Examining the Future: Kiniksa Pharmaceuticals's Earnings Outlook - Benzinga
Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025 - GlobeNewswire
Kiniksa Pharmaceuticals Sets Q1 2025 Earnings Call Date: How to Access Live Results and Portfolio Updates - Stock Titan
Its Stock Has Paid Off Big Time For Kiniksa Pharmaceuticals International Plc - Sete News
Kiniksa Pharmaceuticals introduces new incentive plan By Investing.com - Investing.com India
Kiniksa Pharmaceuticals introduces new incentive plan - Investing.com Australia
Kiniksa Pharmaceuticals chief commercial officer sells $370,475 in stock By Investing.com - Investing.com South Africa
Kiniksa Pharmaceuticals chief commercial officer sells $370,475 in stock - Investing.com Australia
Lacklustre Performance Is Driving Kiniksa Pharmaceuticals International, plc's (NASDAQ:KNSA) Low P/S - simplywall.st
SEC Form DEFA14A filed by Kiniksa Pharmaceuticals International plc - Quantisnow
Analysts Set Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) PT at $37.17 - Defense World
KNSA Stock Sees Decline of Approximately -1.89% in Last Five Days - knoxdaily.com
Kiniksa CFO Mark Ragosa sells shares worth $368,465 By Investing.com - Investing.com South Africa
Kiniksa CFO Mark Ragosa sells shares worth $368,465 - Investing.com India
Kiniksa Pharmaceuticals International Plc (KNSA) 財務データ
収益
当期純利益
現金流量
EPS
0.82%
1.62%
大文字化:
|
ボリューム (24 時間):